Sorrento Therapeutics, Inc.
SRNE
$0.0009
-$0.0001-10.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -7.54% | 4.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.54% | 4.21% | |||
| Cost of Revenue | -14.83% | -10.54% | |||
| Gross Profit | 18.45% | 16.42% | |||
| SG&A Expenses | -10.98% | 39.32% | |||
| Depreciation & Amortization | 0.00% | -0.18% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.66% | 10.21% | |||
| Operating Income | 13.60% | -11.39% | |||
| Income Before Tax | 24.65% | 37.47% | |||
| Income Tax Expenses | -94.15% | 732.19% | |||
| Earnings from Continuing Operations | 29.81% | 31.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -11.23% | 338.63% | |||
| Net Income | 31.80% | 37.59% | |||
| EBIT | 13.60% | -11.39% | |||
| EBITDA | 14.14% | -11.53% | |||
| EPS Basic | 32.83% | 44.31% | |||
| Normalized Basic EPS | 9.37% | 34.37% | |||
| EPS Diluted | 33.58% | 43.92% | |||
| Normalized Diluted EPS | 9.37% | 34.37% | |||
| Average Basic Shares Outstanding | 1.50% | 12.11% | |||
| Average Diluted Shares Outstanding | 1.50% | 12.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||